Thermo Fisher expanded real-world data capabilities through a strategic collaboration with HealthVerity. The deal gives Thermo Fisher’s PPD clinical research business access to HealthVerity’s TaXOnomy claims dataset covering more than 270 million patient records across the US. Thermo Fisher said the dataset and curated marketplace of over 70 data sources will support trial feasibility, recruitment, and real-world evidence generation, including registry-linked claims analytics tied to PPD CorEvitas and PPD Evidera. The company framed the initiative as improving site selection and speeding trial startup timelines. For sponsors, the move adds another layer of claims-derived evidence to complement trial execution and evidence generation workflows—particularly for study feasibility and patient journey mapping.